Cardiovascular Systems, Inc. (CSII) EPS Estimated At $-0.04

January 18, 2018 - By Adrian Erickson

 Cardiovascular Systems, Inc. (CSII) EPS Estimated At $ 0.04
Investors sentiment decreased to 0.79 in 2017 Q3. Its down 0.18, from 0.97 in 2017Q2. It dropped, as 16 investors sold Cardiovascular Systems, Inc. shares while 50 reduced holdings. 10 funds opened positions while 42 raised stakes. 24.82 million shares or 3.05% more from 24.09 million shares in 2017Q2 were reported.
Balyasny Asset Ltd Limited Liability Company owns 14,400 shares or 0% of their US portfolio. First Tru Advisors Lp stated it has 60,314 shares. Alliancebernstein Lp has 0% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII). Svcs Automobile Association owns 113,700 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 2,046 shares. Secor Capital Limited Partnership reported 98,742 shares or 0.26% of all its holdings. Wellington Mgmt Gp Ltd Liability Partnership reported 0.02% in Cardiovascular Systems, Inc. (NASDAQ:CSII). The New York-based Gabelli Funds Ltd Company has invested 0.04% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Trexquant Investment Limited Partnership holds 0.07% in Cardiovascular Systems, Inc. (NASDAQ:CSII) or 9,800 shares. Nuveen Asset Mngmt Limited Liability Company stated it has 46,935 shares. Fred Alger Management reported 443,434 shares. The California-based Schwab Charles Invest Inc has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). 15,836 are owned by Voya Investment Mngmt Ltd. Cubist Systematic Strategies Limited Liability has 0.01% invested in Cardiovascular Systems, Inc. (NASDAQ:CSII). Tiaa Cref Ltd Liability accumulated 215,153 shares or 0% of the stock.

Analysts expect Cardiovascular Systems, Inc. (NASDAQ:CSII) to report $-0.04 EPS on January, 24.They anticipate $0.07 EPS change or 233.33 % from last quarter’s $0.03 EPS. After having $-0.06 EPS previously, Cardiovascular Systems, Inc.’s analysts see -33.33 % EPS growth. The stock increased 3.59% or $0.91 during the last trading session, reaching $26.24. About 388,701 shares traded or 60.87% up from the average. Cardiovascular Systems, Inc. (NASDAQ:CSII) has risen 113.78% since January 18, 2017 and is uptrending. It has outperformed by 97.08% the S&P500.

Cardiovascular Systems, Inc. (NASDAQ:CSII) Ratings Coverage

Among 9 analysts covering Cardiovascular Systems (NASDAQ:CSII), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Cardiovascular Systems has $40 highest and $15 lowest target. $28.80’s average target is 9.76% above currents $26.24 stock price. Cardiovascular Systems had 24 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was initiated by Lake Street on Monday, January 30 with “Buy”. The rating was maintained by Needham on Thursday, August 6 with “Strong Buy”. Zacks upgraded the stock to “Sell” rating in Friday, August 21 report. As per Thursday, September 21, the company rating was initiated by Raymond James. The firm has “Outperform” rating by Leerink Swann given on Monday, August 22. The firm has “Buy” rating given on Friday, July 14 by Needham. The rating was downgraded by Zacks on Monday, August 10 to “Hold”. Needham maintained it with “Buy” rating and $32.0 target in Thursday, January 26 report. The rating was downgraded by Needham on Friday, January 22 to “Underperform”. Needham downgraded the shares of CSII in report on Friday, December 15 to “Hold” rating.

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States. The company has market cap of $895.35 million. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It currently has negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

More news for Cardiovascular Systems, Inc. (NASDAQ:CSII) were recently published by: Zacks.com, which released: “Positive Market Trends Aid Cardiovascular Systems Amid Woes” on January 18, 2018. Businesswire.com‘s article titled: “Cardiovascular Systems Expands Product Portfolio to Further Support Peripheral …” and published on January 18, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.